1. Home
  2. WEX vs CRSP Comparison

WEX vs CRSP Comparison

Compare WEX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WEX Inc. common stock

WEX

WEX Inc. common stock

HOLD

Current Price

$151.72

Market Cap

5.8B

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$57.45

Market Cap

5.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEX
CRSP
Founded
1983
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.6B
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
WEX
CRSP
Price
$151.72
$57.45
Analyst Decision
Hold
Buy
Analyst Count
13
19
Target Price
$172.92
$71.50
AVG Volume (30 Days)
445.6K
2.5M
Earning Date
10-29-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
7.64
N/A
Revenue
$2,624,500,000.00
$38,337,000.00
Revenue This Year
$1.74
N/A
Revenue Next Year
$4.34
$723.84
P/E Ratio
$20.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$110.45
$30.04
52 Week High
$188.70
$78.48

Technical Indicators

Market Signals
Indicator
WEX
CRSP
Relative Strength Index (RSI) 55.84 53.77
Support Level $142.86 $51.16
Resistance Level $155.14 $59.77
Average True Range (ATR) 4.56 3.11
MACD 1.46 1.10
Stochastic Oscillator 83.04 83.07

Price Performance

Historical Comparison
WEX
CRSP

About WEX WEX Inc. common stock

WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. The company's prime end market is the United States of America.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: